ClinicalTrials.Veeva

Menu

Pharmacokinetics of Melatonin Niosomes Oral Gel in Healthy Volunteers

K

Khon Kaen University

Status and phase

Unknown
Phase 2
Phase 1

Conditions

Pharmacokinetics of Melatonin

Treatments

Drug: Melatonin

Study type

Interventional

Funder types

Other

Identifiers

NCT02845778
IN58358

Details and patient eligibility

About

Melatonin is an endogenous hormone. It is able to promote nighttime sleeping and could induce sleep at daytime in adult and children with the nonpainful diagnostic procedure. However, previous formulation had problems of unstability of product and low oral bioavailability. Melatonin niosomes oral gels are formulated in order to overcome the problem of drug absorption and stability. This study is a randomized, double-blind, three phase crossover design in 15 male volunteers. Melatonin niosomes oral gel will be applied at doses 2.5, 5, and 10 mg with 7 days washout for each period. The pharmacokinetics data, sleep induction effect, and adverse event will be determined.

Full description

This study will determine the pharmacokinetics, sleep induction effect, and adverse event after apply melatonin niosomes (MN) oral gel 2.5, 5, and 10 mg per dose in 15 male healthy volunteers. The pharmacokinetic parameters include maximum plasma concentration (Cmax), area under the curve (AUC), time to peak concentration (Tmax), elimination half-life (t1/2). Sleep induction will be determined as sleep onset and duration after use MN oral gels using actigraph and behavior observation. A polysomnography using electrode placement derive from multiple sleep latency test (MSLT) protocol will be used in some subjects. Adverse event will be evaluated by investigator.

Enrollment

15 estimated patients

Sex

Male

Ages

18 to 30 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • male
  • age 18-30 years
  • body mass index 18.5-25 kg/m2
  • general good health and no underlying disease by physical examination and laboratory testing (blood urea nitrogen, creatinine, bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, complete blood count)
  • provide signed informed consent for study participation

Exclusion criteria

  • history of allergies to melatonin products
  • use of any drugs, vitamins, or supplements within 30 days before participation
  • smoke or alcohol consumption within 1 week before participation
  • blood or plasma donation within 30 days before participation

Trial design

15 participants in 3 patient groups

melatonin niosomes oral gel 2.5 mg
Experimental group
Description:
apply onto oral mucosa as single use
Treatment:
Drug: Melatonin
melatonin niosomes oral gel 5 mg
Experimental group
Description:
apply onto oral mucosa as single use
Treatment:
Drug: Melatonin
melatonin niosomes oral gel 10 mg
Experimental group
Description:
apply onto oral mucosa as single use
Treatment:
Drug: Melatonin

Trial contacts and locations

1

Loading...

Central trial contact

Chatchanok Nukulkit, ฺBSc(Pharm); Supawan Laohasiriwong, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems